Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Burden

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Dermatology and Therapy|November 5, 2022
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular PsoriasisAkimichi Morita, Siew Eng Choon, Hervé Bachelez, et al.
The New England Journal of Medicine|March 12, 2019
Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular PsoriasisHervé Bachelez, Siew-Eng Choon, Slaheddine Marrakchi, et al.
Trials|August 31, 2018
A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trialVictoria Cornelius, Rosemary Wilson, Suzie Cro, et al.
The Journal of Investigative Dermatology|August 30, 2016
Spread of Psoriasiform Inflammation to Remote Tissues Is Restricted by the Atypical Chemokine Receptor ACKR2Kave Shams, Gillian J Wilson, Mark Singh, et al.
American Journal of Human Genetics|July 31, 2002
Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locusColin D Veal, Francesca Capon, Michael H Allen, et al.
The Journal of Investigative Dermatology|January 19, 2005
The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasisMichael Hugh Allen, Hahreen Ameen, Colin Veal, et al.
JAMA Dermatology|March 29, 2018
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIRKayleigh J Mason, Jonathan N W N Barker, Catherine H Smith, et al.
The Journal of Investigative Dermatology|November 17, 2015
Establishing an Academic-Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant TherapyChristopher E M Griffiths, Michael R Barnes, A David Burden, et al.
The Journal of Investigative Dermatology|July 14, 2024
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1Ahmed Farag, Sudha Visvanathan, Hervé Bachelez, et al.
Human Genetics|June 26, 2007
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasisFrancesca Capon, Paola Di Meglio, Joanna Szaub, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Dermatology and Therapy|November 5, 2022
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular PsoriasisAkimichi Morita, Siew Eng Choon, Hervé Bachelez, et al.
The New England Journal of Medicine|March 12, 2019
Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular PsoriasisHervé Bachelez, Siew-Eng Choon, Slaheddine Marrakchi, et al.
Trials|August 31, 2018
A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trialVictoria Cornelius, Rosemary Wilson, Suzie Cro, et al.
The Journal of Investigative Dermatology|August 30, 2016
Spread of Psoriasiform Inflammation to Remote Tissues Is Restricted by the Atypical Chemokine Receptor ACKR2Kave Shams, Gillian J Wilson, Mark Singh, et al.
American Journal of Human Genetics|July 31, 2002
Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locusColin D Veal, Francesca Capon, Michael H Allen, et al.
The Journal of Investigative Dermatology|January 19, 2005
The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasisMichael Hugh Allen, Hahreen Ameen, Colin Veal, et al.
JAMA Dermatology|March 29, 2018
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIRKayleigh J Mason, Jonathan N W N Barker, Catherine H Smith, et al.
The Journal of Investigative Dermatology|November 17, 2015
Establishing an Academic-Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant TherapyChristopher E M Griffiths, Michael R Barnes, A David Burden, et al.
The Journal of Investigative Dermatology|July 14, 2024
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1Ahmed Farag, Sudha Visvanathan, Hervé Bachelez, et al.
Human Genetics|June 26, 2007
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasisFrancesca Capon, Paola Di Meglio, Joanna Szaub, et al.
Pageof 9